Related Experiment Video
Updated: Dec 25, 2025

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad, Pakistan
Farah Naz Qamar1, Mohammad Tahir Yousafzai2, Asif Khaliq1
1Dept. of Pediatrics and Child Health, Aga Khan University Karachi, Pakistan.
Insights
The Typhoid Conjugate Vaccine (Typbar-TCV®) was found safe in a large-scale vaccination campaign in Pakistan. Adverse events following immunization were mostly mild, with fever being the most common, and no serious events were reported.
Area of Science:
- Public Health
- Vaccinology
- Infectious Disease Epidemiology
Background:
- Pakistan faces a significant outbreak of extensively drug-resistant (XDR) Typhoid.
- Typhoid Conjugate Vaccine (Typbar-TCV®) was deployed in a high-risk area to combat the outbreak.
Purpose of the Study:
- To evaluate the safety and document adverse events following immunization (AEFI) of Typbar-TCV® in children during an outbreak.
- To assess the safety profile of Typbar-TCV® in a large-scale vaccination campaign.
Main Methods:
- A vaccination campaign was conducted for children aged 6 months to 10 years in Hyderabad, Pakistan.
- AEFI were monitored through a 24/7 hotline and active follow-up of a subset of children.
- AEFI were examined by medical officers using Brighton collaboration criteria.
Main Results:
- A total of 499 AEFI were reported, with a higher incidence in younger children (6-12 months) compared to 2-3 year olds.
- Fever was the most frequent AEFI, reported at 0.02% via hotline and 2.89% in active follow-up.
- No serious adverse events following immunization were observed during the campaign.
Conclusions:
- The administration of a single dose of Typbar-TCV® in children aged 6 months to 10 years is safe.
- The vaccination campaign in an outbreak setting in Hyderabad, Pakistan, demonstrated a favorable safety profile for Typbar-TCV®.
Abstract:
Pakistan is facing the world's largest outbreak of extensively drug-resistant (XDR) Typhoid. Vaccination campaign for children aged 6 months to 10 years old with Typhoid Conjugate Vaccine (Typbar-TCV®) was conducted in high-risk areas of Hyderabad during 2018. About 207,000 children were vaccinated. Here we report the adverse events following immunization (AEFI) during the campaign. The campaign was carried out using outreach and fixed centre strategy. Community mobilizers visited each household to perform line listing and mobilize parents with age-eligible children. Children were observed for 30 min post-vaccination. Two-pronged strategy was used for ascertainment of AEFI. A 24/7 hotline number was provided to all parents/caretakers (n = 199,861) to report AEFI during 14 days following immunization. An age-stratified (n = 7139 children) were actively followed at days 7 and 14 for the ascertainment of AEFI. All AEFI were examined by three trained medical officers. A structured questionnaire using Brighton collaboration criteria with level 3 diagnostic certainty was used for the recording of AEFI. Data were analysed using Microsoft Excel Office 365. Overall, 499 AEFI (433 in the subset actively followed and 66 self-reported through hotline) were observed. The rate of AEFI was significantly higher among very young children (age group 6 to 12 months) as compared to 2 to 3 years old children (0.54% vs. 0.33% respectively; p-value < 0.001). Fever was the most common AEFI self-reported through the hotline (38/199,861 = 0.02%) and among the subset followed actively for 14 days (206/7139 = 2.89%). Fever was followed by local reactogenicity 10/199,861(0.01%), and 134/7139 (1.88%) through self-reported hotline and active follow-up, respectively. No serious AEFI was observed. Administration of a single dose of Typbar-TCV among children aged 6 months to 10 years old during an outbreak setting of Hyderabad Pakistan was safe.
More Related Videos
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
Related Concept Videos
Vaccinations
Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Steps in Outbreak Investigation